Physician profile
Nicolas P Saikali
NPI 1821228511
$1,511,500.63
in general payments reported to CMS, 2019-2025
83 companies · $142K in 2025
The $142K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $172K · 2020: $266K · 2021: $325K · 2022: $234K · 2023: $178K · 2024: $195K · 2025: $142K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $286K · Consulting Fee: $88K · Honoraria: $85K · Travel and Lodging: $32K · Food and Beverage: $23K · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $286,270.00 |
| Consulting Fee | $88,260.63 |
| Honoraria | $84,989.00 |
| Travel and Lodging | $32,015.11 |
| Food and Beverage | $22,980.16 |
| Education | $253.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $562,686.33 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $241,574.03 | 2019-2022 | |
| Amgen INC. | $195,067.77 | 2019-2024 | Aimovig |
| Lundbeck LLC | $111,652.81 | 2019-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $110,471.26 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $91,230.01 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Biohaven Pharmaceutical Holding Company Ltd. | $56,748.00 | 2022 | |
| Impel Pharmaceuticals INC. | $43,708.38 | 2022-2023 | Trudhesa |
| Axsome Therapeutics, INC. | $42,856.70 | 2024-2025 | Symbravo |
| Lilly USA, LLC | $14,960.58 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Promius Pharma LLC | $10,652.52 | 2019 | |
| Bausch Health US, LLC | $3,750.00 | 2024-2025 | |
| Avanir Pharmaceuticals, INC. | $3,390.32 | 2019-2022 | |
| Tonix Medicines, INC. | $3,096.11 | 2023-2025 | Zembrace Symtouch |
| Pfizer INC. | $2,622.82 | 2021-2025 |
Show all 82 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $2,036.31 | 2019-2023 | |
| Livanova USA, INC. | $1,716.85 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Mdd US Operations, LLC | $1,236.35 | 2020-2025 | Gocovri, Apokyn, Gocovri |
| H. Lundbeck A S | $1,213.00 | 2024 | Vyepti |
| Supernus Pharmaceuticals, INC. | $1,181.80 | 2019-2025 | Qelbree |
| Ucb, INC. | $1,136.27 | 2019-2025 | Nayzilam, Rystiggo, Briviact |
| Novartis Pharmaceuticals Corporation | $963.37 | 2019-2021 | |
| Assertio Therapeutics, INC. | $827.37 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $530.97 | 2024-2025 | |
| Eisai INC. | $430.37 | 2019-2025 | |
| Zyla Life Sciences, INC. | $398.53 | 2019-2020 | |
| Sk Life Science, INC. | $362.98 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $343.00 | 2021-2025 | Ultomiris |
| Kestra Medical Technology Services, INC. | $331.85 | 2023-2025 | Assure Wcd |
| Jazz Pharmaceuticals INC. | $290.50 | 2022-2025 | Xywav |
| Biogen, INC. | $244.97 | 2022-2024 | Tysabri, Vumerity |
| Ge Healthcare | $236.14 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $227.56 | 2019-2025 | Onzetra Xsail, Contrave |
| Azurity Pharmaceuticals, INC. | $222.71 | 2023-2025 | Horizant, Eprontia, Zonisade |
| Impel Pharmaceuticals LLC | $212.60 | 2024-2025 | Trudhesa |
| Neurocrine Biosciences, INC. | $181.64 | 2020-2024 | Ingrezza, Ongentys |
| Ipsen Biopharmaceuticals, INC | $178.26 | 2020-2025 | Dysport |
| Acadia Pharmaceuticals INC | $159.86 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $154.25 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $150.57 | 2022 | |
| Eli Lilly and Company | $150.42 | 2019-2023 | Emgality |
| Banner Life Sciences, LLC | $130.05 | 2021-2022 | |
| Greenwich Biosciences, INC. | $109.21 | 2019-2021 | |
| Grt US Holding, INC. | $108.91 | 2022 | |
| W. L. Gore & Associates, INC. | $103.37 | 2019 | |
| Harmony Biosciences LLC | $102.91 | 2021 | |
| Merck Sharp & Dohme LLC | $90.09 | 2022-2024 | Welireg |
| Catalyst Pharmaceuticals, INC. | $85.60 | 2023-2025 | Fycompa |
| Amneal Pharmaceuticals LLC | $75.76 | 2019-2025 | Lyvispah, Brekiya |
| Csl Behring | $75.24 | 2023-2025 | Hizentra |
| Boston Scientific Corporation | $68.42 | 2023 | Watchman Access System |
| Grifols USA, LLC | $66.48 | 2022-2025 | Gamunex-C |
| Acorda Therapeutics, INC | $63.64 | 2019-2023 | Inbrija, Ampyra |
| Takeda Pharmaceuticals U.S.A., INC. | $63.45 | 2019-2025 | Hyqvia |
| Tg Therapeutics, INC. | $59.68 | 2024 | |
| Adamas Pharmaceuticals, INC. | $57.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $50.30 | 2021-2022 | |
| Horizon Therapeutics Plc | $43.61 | 2019-2023 | Krystexxa |
| Averitas Pharma INC. | $40.40 | 2025 | Qutenza |
| Sunovion Pharmaceuticals INC. | $36.98 | 2020-2021 | |
| Tanabe Pharma America, INC. | $32.47 | 2023-2024 | |
| Genzyme Corporation | $32.28 | 2019-2021 | |
| Octapharma USA, INC. | $32.03 | 2023 | Panzyga |
| Argenx US, INC. | $31.71 | 2024 | Vyvgart Hytrulo |
| Endo Pharmaceuticals INC. | $29.86 | 2019 | |
| Neurelis, INC. | $28.68 | 2023-2025 | Valtoco |
| Astrazeneca Pharmaceuticals Lp | $26.47 | 2021-2025 | Wainua |
| Merz North America, INC. | $23.63 | 2019 | |
| Mirum Pharmaceuticals, INC. | $21.99 | 2024 | Cholbam |
| Akcea Therapeutics, INC. | $21.67 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.29 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $20.49 | 2023 | Nuedexta |
| Springworks Therapeutics, INC. | $19.39 | 2025 | Gomekli |
| Vanda Pharmaceuticals INC. | $18.76 | 2019 | |
| Neos Therapeutics, Lp | $18.08 | 2019 | |
| Novo Nordisk INC | $17.59 | 2024 | Wegovy |
| Ibsa Pharma INC. | $16.70 | 2024 | Licart, Tirosint |
| Celgene Corporation | $15.30 | 2025 | Zeposia |
| Alnylam Pharmaceuticals INC. | $14.78 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.18 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $13.87 | 2023 | Relyvrio |
| Novocure INC. | $12.13 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,157.70 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$530,592.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Saikali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.